Laura Joszt, MA

During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.

President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients with intermediate-risk acute myeloid leukemia (AML).

The Commonwealth Fund’s updated July 2025 brief on maternal mortality highlights how systemic disparities, Medicaid coverage gaps, and behavioral health challenges continue to drive poor maternal and infant outcomes across the United States.

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.

US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern and Midwestern regions, according to Muhammad Faizan, MBBS.

Nurses enhance chronic kidney disease (CKD) care by implementing a palliative CKD care framework, addressing barriers, and promoting patient-centered supportive strategies globally.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.

Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite various treatment approaches, highlighting an urgent need for more effective and sustained therapies to improve their quality of life.

Ayodeji Adegunsoye, MD, PhD, MSc, highlights how the underrepresentation of minority populations in pulmonary fibrosis genetic studies hinders accurate disease risk prediction and broader clinical translation.

In a webinar, experts discussed cardiovascular disease prevention strategies, emphasizing personalized risk assessments and emerging treatments to combat this health crisis.

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

An AI model significantly outperformed cardiologists when reviewing ECGs of structural heart disease and may potentially be a step towards increased access and lower costs for early detection of conditions like heart failure and valvular heart disease.

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response rates, manageable dosing schedule, and reduced treatment burden.

The majority of patients with heart failure who qualified for sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy did not receive treatment; a recent study aims to find out why and measure prescription trends.

The potential of health care technology has been disconnected from patients, making those innovations barriers rather than means of improving access and communication.

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Investigators sought to measure and attribute out-of-pocket costs to cancer stage and by diagnosis.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.

Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of The University of Arizona.

In part 2, Hans Lee, MD, shares practical tips for using linvoseltamab in heavily pretreated multiple myeloma and outlines trials that may expand its future role.

The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of the research journey to foster more equitable, transparent, and responsive health care systems.

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and de-escalation to monthly maintenance.